US · ATOS
Atossa Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Seattle, WA 98104
- Website
- atossatherapeutics.com
Price · as of 2024-12-31
$5.33
Market cap 38.15M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | $18,684.00 | $13,174.73 | $0.00 | $0.00 | $0.00 |
| 2013 | $4,887.00 | $17,590.16 | $0.00 | $0.00 | $0.00 |
| 2014 | $5,211.00 | $3,284.80 | $0.00 | $0.00 | $134,017.20 |
| 2015 | $864.00 | $1,289.66 | $0.00 | $0.00 | $124,707.04 |
| 2016 | $270.00 | $45,601.49 | |||
| 2017 | $117.00 | ||||
| 2018 | $22.50 | ||||
| 2019 | $17.70 | ||||
| 2020 | $43.65 | ||||
| 2021 | $18.15 | ||||
| 2022 | $10.05 | ||||
| 2023 | $16.35 | ||||
| 2024 | $11.10 |
AI valuation
Our deep-learning model estimates Atossa Therapeutics, Inc.'s (ATOS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $5.33
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ATOS | Atossa Therapeutics, Inc. | $5.33 | 38.15M | — | — | — | — | -3.65 | 1.30 | — | -0.80 | — | 1.30 | 0.00% | — | — | -31.39% | -1873.25% | -29.54% | 0.00 | — | 14.99 | 14.31 | 2.58 | -1667.00% | — | 45.00% | -22.60% | -4.23 | -1427.53% | 0.00% | 0.00% | 0.00% | -0.80 | -1.05 | — | 7.27 |
| CGTX | Cognition Therapeutics, I… | $1.09 | 80.2M | — | — | — | — | -0.50 | 0.91 | — | 0.21 | — | 0.91 | 0.00% | — | — | -157.19% | 1117.89% | -103.89% | 0.04 | -2158.64 | 2.65 | 2.49 | 0.72 | -116.00% | — | 7617.00% | -167.08% | -2.56 | 589.91% | 0.00% | 0.00% | 0.00% | 0.13 | 0.25 | — | -12.38 |
| CLNN | Clene Inc. | $5.23 | 48.62M | +633% | -65% | — | +3,976% | -0.81 | -3.60 | 93.13 | -1.20 | — | -3.60 | 79.53% | -9676.32% | -11520.47% | -1738.36% | -637.51% | -98.90% | -2.35 | -8.14 | 1.57 | 1.22 | -0.26 | -3987.00% | -4771.00% | -3003.00% | -67.00% | -2.07 | -411.12% | 0.00% | 0.00% | 0.00% | -1.22 | -1.90 | 118.53 | -17.65 |
| COYA | Coya Therapeutics, Inc. | $4.96 | 82.41M | +515% | -78% | — | +508% | -7.05 | 2.65 | 29.50 | -3.87 | -29.29 | 2.65 | -233.86% | -485.35% | -418.70% | -39.57% | -774.97% | -34.76% | 0.00 | — | 11.59 | 10.22 | 2.23 | 2405.00% | -4079.00% | -804.00% | -9.81% | -2.69 | -484.62% | 0.00% | 0.00% | 5.45% | -3.86 | -6.46 | 18.71 | 11.79 |
| GLSI | Greenwich LifeSciences, I… | $27.72 | 384.05M | — | — | — | — | -9.97 | 62.14 | — | -9.72 | -13.23 | 62.19 | 0.00% | — | — | -341.95% | 1733.85% | -284.78% | 0.00 | — | 2.62 | 2.62 | 0.26 | 7536.00% | — | 1216.00% | -4.61% | -4.66 | 786.86% | 0.00% | 0.00% | 0.00% | -9.58 | -21.11 | — | 25.79 |
| IMMX | Immix Biopharma, Inc. | $8.07 | 270.94M | — | — | — | — | -1.99 | 3.24 | — | -1.17 | — | 3.24 | 0.00% | — | — | -145.76% | 1016.65% | -100.83% | 0.08 | — | 2.33 | 2.26 | 0.74 | -1461.00% | — | 3807.00% | -36.69% | -1.68 | 707.20% | 0.00% | 0.00% | 0.00% | -1.16 | -1.67 | — | -4.58 |
| ONCY | Oncolytics Biotech Inc. | $1.13 | 113.41M | — | — | — | — | -2.33 | 12.32 | — | -1.69 | — | 12.32 | 0.00% | — | — | -189.05% | 442.22% | -107.48% | 0.18 | — | 2.82 | 2.39 | 0.43 | 0.00% | — | -440.00% | -36.90% | -4.03 | 343.91% | 0.00% | 0.00% | 0.00% | -1.68 | -2.16 | — | -35.01 |
| SRZN | Surrozen, Inc. | $27.80 | 238.29M | — | -83% | — | — | -0.55 | -1.64 | 3.28 | -0.37 | -34.54 | -1.64 | 100.00% | -239.69% | -596.56% | -767.91% | 121.02% | -134.46% | -0.40 | — | 5.32 | 5.07 | 1.08 | 159.00% | — | -5669.00% | -50.45% | -2.41 | 83.66% | 0.00% | 0.00% | 0.00% | -0.35 | -0.50 | 0.84 | -8.68 |
| TIL | Instil Bio, Inc. | $8.90 | 60.36M | — | — | — | — | -1.61 | 0.70 | — | -1.48 | — | 0.70 | 0.00% | — | — | -37.51% | -48.30% | -25.16% | 0.51 | -8.18 | 15.76 | 14.35 | -1.25 | -5254.00% | — | -3603.00% | -55.11% | -7.05 | -43.15% | 0.00% | 0.00% | 0.00% | -1.26 | -1.41 | — | -3.11 |
| TVGN | Tevogen Bio Holdings Inc. | $0.26 | 53.24M | — | — | — | — | -12.18 | -25.05 | — | -12.85 | -0.05 | -25.05 | 0.00% | — | — | 27.16% | 2087.12% | -306.17% | -0.43 | -291.05 | 0.26 | 0.16 | -0.12 | 2330000.00% | — | 4449.00% | -7.18% | -1.33 | 467.53% | 0.00% | 0.00% | 55.48% | -3.15 | -14.07 | — | -89.34 |
| WHWK | Whitehawk Therapeutics In… | $3.51 | 165.42M | +472% | -63% | — | — | -0.90 | 1.09 | 2.21 | -0.17 | — | 1.09 | -108.04% | -259.62% | -245.13% | -80.79% | -3655.27% | -62.83% | 0.02 | -438.04 | 3.59 | 3.11 | 0.43 | -328.00% | 669.00% | -382.00% | -106.81% | -3.49 | -3316.39% | 0.00% | 0.00% | 0.00% | -0.16 | -0.18 | 0.42 | -6.74 |
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
- CEO
- Steven C. Quay
- Employees
- 15
- Beta
- 1.34
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $5.33) − 1 = — (DCF, example).